

Relationship between severity of asthma And high sensitivity C – reactive protein

Thesis

Submitted for fulfillment of the Master Degree in Chest Diseases
And tuberculosis

Presented by

Ibrahim Abouelkhair Hassan montasser

Under supervision of

Prof. Mohammed Galal Morsi

Professor of Chest disease Department

Faculty of Medicine – Cairo University

Prof. Mohammed Shehata

Professor of clinical & chemical pathology

Faculty of Medicine – Cairo University

Dr. Hassan Mahmoud Amen

Assistant Professor of Chest disease Department

Faculty of Medicine

Cairo University

Acknowledgement

First of all, I would like to express my prayerful thanks to **ALLAH** for everything

I would like to express my unlimited gratitude and appreciation to **Prof. Mohammed Galal**, professor of Chest Diseases; Kasr El - Aini faculty of Medicine. I`m deeply grateful to him for his supervision, support and continuous encouragement during this work

I am very grateful to **Prof. Mohammed Shehata**, Professor of Clinical & chemical pathology; Kasr El - Aini faculty of Medicine, for his precious supervision

I would like to express my sincere thanks to **Dr. Hassan Mahmoud Amen**, Assistant Professor of Chest Diseases; Kasr El - Aini faculty of Medicine, for his precious advise, encouragement and support during his work

Ibrahim Abouelkhair Hassan montasser

CONTENTS

Title	page
Introduction	1
Aim of the work.....	4
Review of Literature.....	6
Subjects and Methods.....	102
Results.....	106
Discussion.....	118
Summary and Conclusions	124
Recommendations.....	127
References.....	128
Arabic summary.....	*

LIST OF TABLES

NO	Name of the table	page
Review		
Table(1)	key indicators for considering a diagnosis of asthma	30
Table(2)	medical history	31
Table(3)	differential diagnostic possibilities for asthma	36
Table(4)	Initial assessment of asthma	37
Table(5)	Levels of Asthma Control	49
RESULTS		
Table(1)	Age and Sex of the two studied groups	107
Table(2)	Symptoms of the asthmatic patients	108
Table(3)	Demographic and clinical characteristics of control and asthmatic	109
Table(4)	High sensitivity C - reactive protein (hs –CRP) in asthmatic patients and control persons	113
Table(5)	Correlation coefficient (r) of HS-CRP with ESR, TLC, Eosinophil (%) and FEV1in total asthmatic studied groups	114

LIST OF FIGURES

NO	Name of the figure	page
Review		
Figure(1)	The interplay and interaction between airway inflammation and the clinical symptoms and pathophysiology of asthma	8
Figure(2)	Factors limiting airflow in acute and persistent asthma	11
Figure(3)	airway inflammation	15
Figure(4)	Host Factors and environmental exposure	18
Figure(5)	Cytokine balance	20
Figure(6)	Classifying asthma severity	53
Figure(7)	Summary of measure and control of environmental factors that can make asthma worse	60
Figure(8)	Stepwise approach for management asthma in youths ≥ 12 years of age and adults	91
Figure(9)	classifying asthma severity and initiating treatment in youths ≥ 12 years of age and adult	92
RESULTS		
Figure(1)	Mean age of the two studied groups	107
Figure(2)	Degree of Dyspnea in asthmatic groups	108

Figure(3)	Total leucocyte count of the four studied groups	110
Figure(4)	Eosinophil percentage of the four studied groups	110
Figure(5)	Erythrocyte sedimentation rate (ESR) at 1 and 2 hours in the four studied groups	111
Figure(6)	pH of the four studied groups	111
Figure(7)	PO ₂ and PCO ₂ of the four studied groups	112
Figure(8)	SO ₂ % of the four studied groups	112
Figure(9)	median hs-CRP in control persons and asthmatic patients	113
Figure(10)	Results of respiratory function test (FEV ₁) in the four studied groups	114
Figure(11)	Correlation between HS-CRP and : ESR ₁ in asthmatic patients	115
Figure(12)	Correlation between HS-CRP and ESR ₂ in asthmatic patients	115
Figure(13)	Correlation between HS-CRP and TLC in asthmatic patients	116
Figure(14)	Correlation between HS-CRP and Eosinophil (%) in asthmatic patients	116
Figure(15)	Correlation between HS-CRP and FEV ₁ in asthmatic patients	117
Figure(16)	Correlation between control HS-CRP and asthmatic patients	117

LIST OF ABBREVIATIONS

ABG arterial blood gas
ABPA allergic bronchopulmonary aspergillosis
ACE angiotensin converting enzyme
AHRQ Agency for Healthcare Research and Quality
ALT alanine aminotransferase
ATS American Thoracic Society
BDP beclomethasone dipropionate
BPT bronchial provocation test
CAMP Childhood Asthma Management Program
CBC complete blood count
CDC Centers for Disease Control and Prevention
CFC chlorofluorocarbon
COPD chronic obstructive pulmonary disease
COX-2 cyclooxygenase
CPAP continuous positive airway pressure
CT computer tomography
DHHS U.S. Department of Health and Human Services
DPI dry powder inhaler
ED emergency department
EIB exercise-induced bronchospasm
eNO exhaled nitric oxide
EPR Expert Panel Report
EPR 1991, EPR 1997 (EPR—2), EPR—Update 2002,
EPR—3: Full Report 2007 (this 2007 guidelines update)
ER emergency room
ERS European Respiratory Society
FDA U.S. Food and Drug Administration
FEF forced expiratory flow
FEF25–75 forced expiratory flow between 25 percent and 75 percent of the vital capacity
FeNO fractional exhaled nitric oxide

FEV1 forced expiratory volume in 1 second
FiO2 fractional inspired oxygen
FRC functional residual capacity
FVC forced vital capacity
GERD gastro esophageal reflux disease
GINA Global Initiative for Asthma
HFA hydrofluoroalkane (inhaler propellant)
HPA hypothalamic-pituitary-adrenal
ICS inhaled corticosteroid(s)
ICU intensive care unit
IgE immunoglobulin E
IVMg intravenous magnesium sulfate
LABA/LABAs long-acting beta2-agonist(s)
LTRA leukotriene receptor antagonist
MDI metered-dose inhaler
NAEPP National Asthma Education and Prevention Program
NCHS National Center for Health Statistics
NO nitric oxide
NSAID nonsteroidal anti-inflammatory drug
OSA obstructive sleep apnea
PCO2 partial pressure of carbon dioxide
PEF peak expiratory flow
RSV respiratory syncytial virus
RV residual volume
SABA/SABAs short-acting beta2-agonist(s) (inhaled)
SaO2 oxygen saturation
Th1, Th2 T cell helper 1, T cell helper 2
TLC total lung capacity
VC vital capacity
VCD vocal cord dysfunction

ABSTRACT

1. HS-CRP may be used to assess the severity of the disease and response to treatment.
2. HS-CRP may be used as a systemic marker of inflammatory process that occurs in patients with asthma.
3. HS-CRP level is recommended to be studied as a marker for development of exacerbation of asthma
4. HS-CRP level is recommended to be studied as follow up marker during treatment with ICS in stepwise management of asthma

Key words:

Relation between asthma and hsCRP

INTRODUCTION

Introduction

Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role. The chronic inflammation is associated with airway hyper responsiveness that leads to recurrent episodes of wheezing, breathlessness, Chest tightness, and coughing, particularly at night or in the early morning. These episodes are usually associated with widespread, but variable, airflow obstruction within the lung that is often reversible either spontaneously or with treatment (***GINA, 2011***)

C - reactive protein (CRP) was identified by Tilet and Francis (1930) in the plasma of patients with pneumonia, and was named for its ability to bind and precipitate the C-polysaccharide of pneumococcus. It is an alpha globulin with a molecular mass of approximately 110,000 to 140,000 Dalton's, and is composed of five identical subunits, which are noncovalently assembled as a cyclic pentamer. CRP is synthesized in the liver and is normally present as a trace constituent of serum or plasma at levels less than 0.3 mg/dl, Its physiological roles are numerous and varied, but with several functions similar to those of immunoglobulin's, CRP appears to function in host defense. (***Carlson et al., 2005***)

Serum levels of the well-known inflammatory marker C-reactive protein (CRP) can be simply and inexpensively measured in order to assess systemic inflammation. (***Pepys and Baltz, 1983***)

However, standard assays for CRP, with a lower detection limit of 3–8 mg/ L Lack the sensitivity required to determine levels of inflammation the normal range. (***Ridker, 2001***)

High- sensitivity assays for CRP (hs-CRP) have become available in clinical laboratories. Measurement of serum hs-CRP levels has suggested the involvement of low-grade systemic inflammation in several disorders, such as cardiovascular disease and diabetes mellitus. (***Tracy, 1998***)

Furthermore, a recent population- based study showed associations of increased levels of serum hs-CRP with a high frequency of airway hyper responsiveness and low forced expiratory volume in one second (FEV 1) among subjects without heart disease (***Kony et al., 2004***).

Suggesting that systemic inflammation may be associated with respiratory impairment, another recent epidemiological study showed that elevated levels of hs-CRP correlate significantly with respiratory symptoms and with prevalence of nonallergic asthma. **(Olafsdottir et al., 2005)**

Asthma is characterized by airway hyperresponsiveness and inflammation, in which various cells (such as eosinophils, neutrophils, macrophages and T-lymphocytes), cytokines and mediators play a role. Beside local inflammation, systemic inflammation is present in asthma, as shown by increased levels of plasma fibrinogen and serum amyloid A **(Jousilahti et al., 2002)**

Thus hs-CRP could theoretically also be a useful tool for detecting systemic inflammation in asthma; indeed, an association between serum hs-CRP level and severity of asthma has been suggested **(Sävykoski et al., 2004)**

AIM OF THE WORK

Aim of the work

The purpose of this study is to evaluate of high sensitivity C -reactive protein in asthmatic patients in relation to asthma severity.

REVIEW OF LITERATURE